Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis-Reference-Cited by-同舟云学术

Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis

Published:2024-03 Issue: Volume:966 Page:176366
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Kurumiya Eon,Iwata Mayuu,Kasuya Yoshitoshi,Tatsumi Koichiro,Honda Takuya^ORCID,Murayama Toshihiko,Nakamura Hiroyuki^ORCID

Funder

Japan Science and Technology Agency

Chiba University

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Reference19 articles.

1. Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors;Chen;J. Cell. Physiol.,2008

2. Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms a complex with Smad3 and inhibits its transcriptional activity;Grimsby;FEBS Lett.,2004

3. Fibrosis: from mechanisms to medicines;Henderson;Nature,2020

4. Fibroblasts in fibrosis: novel roles and mediators;Kendall;Front. Pharmacol.,2014

5. The arachidonic acid metabolite 11,12-epoxyeicosatrienoic acid alleviates pulmonary fibrosis;Kim;Exp. Mol. Med.,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sumatriptan mitigates bleomycin-induced lung fibrosis in male rats: Involvement of inflammation, oxidative stress and α-SMA;Tissue and Cell;2024-06

2. Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis;2024-02-14